TY - JOUR
T1 - A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia
AU - Duvaldestin, Philippe
AU - Kuizenga, Karel
AU - Saldien, Vera
AU - Claudius, Casper
AU - Servin, Frédérique
AU - Klein, Jan
AU - Debaene, Bertrand
AU - Heeringa, Marten
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Sugammadex is the first of a new class of selective muscle relaxant binding drugs developed for the rapid and complete reversal of neuromuscular blockade induced by rocuronium and vecuronium. Many studies have demonstrated a dose-response relationship with sugammadex for reversal of neuromuscular blockade in patients induced and maintained under propofol anesthesia. However, sevoflurane anesthesia, unlike propofol, can prolong the effect of neuromuscular blocking drugs (NMBDs) such as rocuronium and vecuronium.
AB - Sugammadex is the first of a new class of selective muscle relaxant binding drugs developed for the rapid and complete reversal of neuromuscular blockade induced by rocuronium and vecuronium. Many studies have demonstrated a dose-response relationship with sugammadex for reversal of neuromuscular blockade in patients induced and maintained under propofol anesthesia. However, sevoflurane anesthesia, unlike propofol, can prolong the effect of neuromuscular blocking drugs (NMBDs) such as rocuronium and vecuronium.
U2 - 10.1213/ANE.0b013e3181c3be3c
DO - 10.1213/ANE.0b013e3181c3be3c
M3 - Journal article
C2 - 19933538
SN - 0003-2999
VL - 110
SP - 74
EP - 82
JO - Anesthesia and Analgesia
JF - Anesthesia and Analgesia
IS - 1
ER -